Search results
Results from the WOW.Com Content Network
[6] [7] Simvastatin is available as a generic medication, [4] and is on the World Health Organization's List of Essential Medicines. [8] In 2022, it was the nineteenth most commonly prescribed medication in the United States, with more than 26 million prescriptions. [9] [10]
FDA's role under the guidelines is to monitor company recalls and assess the adequacy of a firm's action. After a recall is completed, FDA makes sure that the product is destroyed or suitably reconditioned and investigates why the product was defective. Generally, FDA accepts reports and other necessary recall information submitted by e-mail.
Sitagliptin: Using male and female rats, a two-year carcinogenicity study was carried out with doses of 50, 150, and 500 mg/kg/day. The 500 mg/kg dose has exposure limits of 60 times what would be seen in the highest dose in humans. At this dose, liver adenoma/carcinoma was seen. Tumors were not seen from the smaller doses.
The class is on the World Health Organization's List of Essential Medicines with simvastatin being the listed medicine. [10] In 2005, sales were estimated at US$18.7 billion in the United States. [11] The best-selling statin is atorvastatin, also known as Lipitor, which in 2003 became the best-selling pharmaceutical in history. [12]
They shared their best practices for taking blood pressure medication, including timing and what to do if you miss a dose. Related: The 4 'Non-Negotiables' Everyone Should Adopt for Optimal Health ...
Costco Recalls. Costco continues pulling products off its shelves as a wave of listeria contamination sweeps the country. Within the past week, the wholesale giant sent separate notices to its ...
Consumers and retailers can identify the products by checking the UPC on the back of the carton, the lot code and best by date. As of Friday, the following brands were included in the TreeHouse ...
The Scandinavian Simvastatin Survival Study (also known as the 4S study), was a multicentre, randomized, double-blind, placebo-controlled clinical trial, which provided the initial data that supported the use of the cholesterol-lowering drug, simvastatin, in people with a moderately raised cholesterol and coronary heart disease (CHD); that is people who had previously had a heart attack or angina.